Prostate Cancer - Results from #300

Fatigue Management in Advanced Prostate Cancer: Real-World Insights From Qualitative Interviews With Patients. September 16, 2024

Comparative Performance of 68Ga-PSMA-11 PET/CT and Conventional Imaging in the Primary Staging of High-Risk Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy. September 16, 2024

Comparison of PSMA immunohistochemistry scoring systems to parametric [18F]PSMA-1007 PET/MRI in primary prostate cancer. September 16, 2024

Effectiveness of ChatGPT 4.0 in Telemedicine-Based Management of Metastatic Prostate Carcinoma. September 16, 2024

Targeted Prostate Biopsy: How, When, and Why? A Systematic Review. September 16, 2024

Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment. September 16, 2024

Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308. September 14, 2024

Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells. September 14, 2024

Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer. September 14, 2024

Association of Baseline Magnetic Resonance Imaging Prostate Imaging Reporting and Data System Score With Prostate Cancer Active Surveillance Early Biopsy Reclassification: Data From the Michigan Urological Surgery Improvement Collaborative (MUSIC) September 13, 2024

SECuRE Trial Advances: No Dose Limiting Toxicities and Strong Preliminary Efficacy Data in First Multi-Dose Cohort September 13, 2024

Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race. September 13, 2024

Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics. September 13, 2024

Quantification of Gleason Pattern 4 Metrics Identifies Pathologic Progression in Patients With Grade Group 2 Prostate Cancer on Active Surveillance. September 13, 2024

Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial. September 13, 2024

Observation With or Without Subsequent Salvage Therapy for Pathologically Node-positive Prostate Cancer With Negative Conventional Imaging: Results From a Large Multicenter Cohort. September 13, 2024

Systematic review and recommendations for re-irradiation for intraprostatic radiorecurrent prostate cancer after definitive radiation therapy. September 13, 2024

Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. September 13, 2024

YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer. September 13, 2024

PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research. September 13, 2024

Page 16 of 1437